Ambulatory use of blinatumomab in paediatric patients with relapsed or refractory B-cell acute lymphoblastic leukaemia at a single centre in South Africa
Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer, with B-ALL comprising approximately 85% of all cases. Despite a high cure rate, those with refractory disease and/or relapsed (R/R) B-ALL have an inferior overall survival. Blinatumomab, a novel therapy, is a bispecific cluster...
| Published in: | South African Journal of Oncology |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2026-05-01
|
| Subjects: | |
| Online Access: | https://sajo.org.za/index.php/sajo/article/view/365 |
| Summary: | Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer, with B-ALL comprising approximately 85% of all cases. Despite a high cure rate, those with refractory disease and/or relapsed (R/R) B-ALL have an inferior overall survival. Blinatumomab, a novel therapy, is a bispecific cluster of differentiation (CD)19-directed CD3 T-cell engager that has proven efficacy in children with R/R B-ALL. It is administered as a 28-day infusion with associated prolonged hospital admissions. To date, there are few publications on its use in paediatric B-ALL, including its use in the outpatient setting.
Contribution: This case series offers additional context and understanding in this regard. |
|---|---|
| ISSN: | 2518-8704 2523-0646 |